Crew Capital Management Ltd. Sells 133 Shares of Abbott Laboratories (NYSE:ABT)

Crew Capital Management Ltd. cut its holdings in shares of Abbott Laboratories (NYSE:ABT) by 3.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,514 shares of the healthcare product maker’s stock after selling 133 shares during the period. Crew Capital Management Ltd.’s holdings in Abbott Laboratories were worth $387,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABT. Boyd Watterson Asset Management LLC OH lifted its holdings in Abbott Laboratories by 1.8% during the third quarter. Boyd Watterson Asset Management LLC OH now owns 25,773 shares of the healthcare product maker’s stock worth $2,496,000 after acquiring an additional 463 shares in the last quarter. ST Germain D J Co. Inc. lifted its holdings in shares of Abbott Laboratories by 0.6% in the third quarter. ST Germain D J Co. Inc. now owns 21,756 shares of the healthcare product maker’s stock valued at $2,107,000 after purchasing an additional 131 shares in the last quarter. FAS Wealth Partners Inc. acquired a new position in shares of Abbott Laboratories during the third quarter worth about $483,000. Compagnie Lombard Odier SCmA bought a new position in shares of Abbott Laboratories during the third quarter worth about $75,766,000. Finally, WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its position in Abbott Laboratories by 29.8% in the 3rd quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 2,700,000 shares of the healthcare product maker’s stock valued at $261,495,000 after buying an additional 620,000 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 963 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $118.50, for a total value of $114,115.50. Following the transaction, the executive vice president now directly owns 125,697 shares of the company’s stock, valued at approximately $14,895,094.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Daniel Gesua Sive Salvadori sold 963 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $114,115.50. Following the transaction, the executive vice president now directly owns 125,697 shares of the company’s stock, valued at $14,895,094.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Andrea F. Wainer sold 12,500 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the transaction, the executive vice president now directly owns 78,704 shares in the company, valued at $9,444,480. The disclosure for this sale can be found here. Insiders have sold a total of 13,935 shares of company stock valued at $1,670,048 in the last three months. 0.47% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Evercore ISI raised their price target on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Citigroup increased their price objective on shares of Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada lowered their target price on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a research report on Thursday, April 18th. Raymond James reissued a “buy” rating and set a $124.00 price target on shares of Abbott Laboratories in a research report on Wednesday, April 24th. Finally, Barclays dropped their price objective on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a research note on Monday, April 22nd. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $121.50.

Abbott Laboratories Stock Performance

Abbott Laboratories stock traded down $0.26 during mid-day trading on Monday, hitting $107.27. 3,306,017 shares of the company’s stock traded hands, compared to its average volume of 5,632,260. Abbott Laboratories has a fifty-two week low of $89.67 and a fifty-two week high of $121.64. The stock has a market cap of $186.13 billion, a price-to-earnings ratio of 33.66, a P/E/G ratio of 2.59 and a beta of 0.74. The firm has a 50 day simple moving average of $113.64 and a two-hundred day simple moving average of $108.22. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.64 and a quick ratio of 1.16.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 EPS for the quarter, topping the consensus estimate of $0.96 by $0.02. The business had revenue of $9.96 billion during the quarter, compared to the consensus estimate of $9.88 billion. Abbott Laboratories had a net margin of 13.96% and a return on equity of 20.32%. Abbott Laboratories’s revenue was up 2.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.03 EPS. On average, research analysts expect that Abbott Laboratories will post 4.62 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be issued a $0.55 dividend. The ex-dividend date is Friday, April 12th. This represents a $2.20 annualized dividend and a yield of 2.05%. Abbott Laboratories’s dividend payout ratio is currently 68.54%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.